Keyphrases
Gli1
100%
Antitumor Efficacy
100%
DYRK1A
100%
Therapeutic Target
20%
Phosphorylation
20%
Breast Cancer
20%
DYRK1A Inhibitor
13%
Pharmacological Inhibitors
13%
Cancer Cell Growth
13%
Nuclear Translocation
13%
Hedgehog Signaling Pathway
13%
In Vivo Efficacy
13%
Transcription Factor
13%
Hedgehog
13%
Pathway Activity
6%
Therapeutic Value
6%
Invasiveness
6%
Vismodegib
6%
Phosphorylation Sites
6%
New Tumor
6%
3D Spheroid Models
6%
Hedgehog Inhibitor
6%
Predictors of Poor Prognosis
6%
Low Potencies
6%
High-throughput Screening
6%
Acquired mutations
6%
Early Phase Clinical Trials
6%
Anticancer Therapeutics
6%
Developmental Signaling Pathways
6%
Novel Mechanism
6%
Lack of Understanding
6%
Overexpressing
6%
Hedgehog Signaling
6%
Gene Amplification
6%
Drug Resistance
6%
Knockdown
6%
Transcriptional Activity
6%
Pancreatic Cancer
6%
Downstream Effectors
6%
Direct Target
6%
Overexpression
6%
Tumorigenesis
6%
Cancer Cell Proliferation
6%
Xenograft Model
6%
Strong Predictor
6%
Sonidegib
6%
New Therapeutic Approaches
6%
Clinical Inhibitors
6%
Glioma Cancer
6%
Brain Glioma
6%
Tumor Selectivity
6%
Tumor Growth
6%
Nuclear Expression
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Hedgehog
100%
Malignant Neoplasm
83%
Cancer Growth
33%
Breast Cancer
33%
Transcription Factors
33%
Drug Resistance
16%
Pancreas Cancer
16%
Clinical Trial
16%
Glioma
16%
Sonidegib
16%
Tumor Growth
16%
Vismodegib
16%
Preclinical Study
16%
Carcinogenesis
16%
Phosphotransferase
16%
Biochemistry, Genetics and Molecular Biology
DYRK1A
100%
GLI1
100%
Hedgehog Signaling Pathway
26%
Cancer Cell
13%
Cell Growth
13%
Transcription Factors
13%
Hedgehog
13%
Preclinical Study
6%
Drug Resistance
6%
Carcinogenesis
6%
Phosphotransferase
6%
Kinase
6%
Clinical Trial
6%
Cell Proliferation
6%
Tumor Spheroid
6%
Transcription Initiation
6%
Genetics
6%
Tumor Progression
6%
Signal Transduction
6%
Gene Amplification
6%
Vismodegib
6%